Cisplatin　(CDDP)　has　been　considered　as　one　of　the　most　effective　anticancer　drugs　against　cervical　cancer,　but　the　lack　of　selectivity　of　CDDP　to　tumor　tissues　often　leads　to　serious　toxic　side　effects.　In　this　study,　CDDP-incorporated　CyS.S-PEG-g-A-HA　nanoparticles　were　prepared　to　endue　CDDP　the　ability　to　selectively　target　tumors　and　fluorescence　imaging　in　vivo.　The　nanoparticles　exhibited　a　spherical　shape　with　particle　sizes　between　216.4　and　281.5　nm　and　had　a　pH　and　Cl-　concentration　dependence　on　controlled　and　sustained　CDDP　release,　which　was　favorable　for　nanoparticles　to　release　more　drugs　at　acidic　tumor　microenvironment.　Cell　biology　experiments　demonstrated　that　the　nanoparticles　had　good　biocompatibility　and　tumor　targeting;　the　nanoparticles　could　selectively　bind　and　internalize　into　HeLa　cells　and　induce　apoptosis,　but　lead　cytotoxicity　on　NIH3T3　cells.　What　is　more,　the　nanoparticles　could　be　clearly　fluorescent-imaged　in　vivo　and　showed　effective　accumulation　at　the　tumor　site.　Antitumor　test　in　vivo　displayed　that　the　nanoparticles　had　good　antitumor　efficiency　and　low　systemic　toxicity　which　improved　the　life　quality　of　mice.　Hence,　the　CDDP-incorporated　Cy5.5-PEG-g-A-HA　nanoparticles　were　a　potential　delivery　system　for　targeting　delivery　of　CDDP　against　cervical　cancer.